Cargando…
In Vivo Evaluation of the Acute Pulmonary Response to Poractant Alfa and Bovactant Treatments in Lung-Lavaged Adult Rabbits and in Preterm Lambs with Respiratory Distress Syndrome
BACKGROUND: Poractant alfa (Curosurf(®)) and Bovactant (Alveofact(®)) are two animal-derived pulmonary surfactants preparations approved for the treatment of neonatal respiratory distress syndrome (nRDS). They differ in their source, composition, pharmaceutical form, and clinical dose. How much thes...
Autores principales: | Ricci, Francesca, Salomone, Fabrizio, Kuypers, Elke, Ophelders, Daan, Nikiforou, Maria, Willems, Monique, Krieger, Tobias, Murgia, Xabier, Hütten, Matthias, Kramer, Boris W., Bianco, Federico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583171/ https://www.ncbi.nlm.nih.gov/pubmed/28913327 http://dx.doi.org/10.3389/fped.2017.00186 |
Ejemplares similares
-
In vitro characterization and in vivo comparison of the pulmonary outcomes of Poractant alfa and Calsurf in ventilated preterm rabbits
por: Guo, Xiaojing, et al.
Publicado: (2020) -
Poractant alfa (Curosurf(®)) increases phagocytosis of apoptotic neutrophils by alveolar macrophages in vivo
por: Willems, Coen HMP, et al.
Publicado: (2012) -
Nebulized Poractant Alfa Reduces the Risk of Respiratory Failure at 72 Hours in Spontaneously Breathing Surfactant-Deficient Newborn Piglets
por: Rey-Santano, Carmen, et al.
Publicado: (2020) -
The Use of Exogenous Lung Surfactant (Poractant Alfa) in Acute Respiratory Failure by Drowning
por: Pezzi, Mario, et al.
Publicado: (2020) -
Dose Effect of Poractant Alfa in Neonatal RDS: Analysis of Combined Data from Three Prospective Studies
por: Królak-Olejnik, Barbara, et al.
Publicado: (2020)